Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART

NCT00270205 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

28

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: LC002 standard vaccination
BIOLOGICAL: LC002 high-dose vaccination
BIOLOGICAL: LC002 placebo vaccination

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]